For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
|
Basic information |
Chairman |
President |
Spokesperson |
Telephone |
Address |
ESM Registration Date |
Hsu, Lu-Hui |
Ling, Yu-Fang |
Ling, Yu-Fang |
02-2697-1355 |
32F-9, No.99, Sec. 1, Xintai 5th Rd., Xizhi Dist.,New Taipei City, Taiwan |
2022/12/26 |
Industrycategory |
Key businesses |
Biotechnology and Medical Care |
Caliway Biopharmaceuticals Inc. focuses on breakthrough medical aesthetics and inflammatory medicine discovery of small-molecule therapeutics. We also choose on areas of unmet medical need and target a growing market worth more than $10 billion to expand their market opportunity. Our leading candidate, CBL-514, is a first-in-class new drug that can trigger adipocyte apoptosis at the injection site and effectively reduce the subcutaneous fat without causing tissue necrosis or prominent side effects. The drug has completed Phase 2a trials for non-surgical fat reduction and has shown promising clinical effectiveness and safety and is expected to expand its indications to include Dercum’s disease and cellulite. Our other products in clinical development target osteoarthritis, diabesity, hyperpigmentation and aging skin. We believe Caliway will become a rising star in the Taiwanese pharmaceutical market. |
Financial data |
Cash flows statement
| Item
|
|
|
Amount(NTD, in thousands) |
Cash flows from operating activities |
|
|
Cash flows from investing activities |
|
|
Cash flows from financing activities |
|
|
Consolidated/Individual balance sheet
|
Current assets |
|
|
Non-current assets |
|
|
Total assets |
|
|
Current liabilities |
|
|
Non-current liabilities |
|
|
Total liabilities |
|
|
Share capital |
|
|
Capital surplus |
|
|
Retained earnings |
|
|
Other equity interest |
|
|
Treasury shares |
|
|
Total equity attributable to owners of parent |
|
|
Non-controlling interests |
|
|
Total equity |
|
|
Book Value per share(NT$) |
|
|
Consolidated/Individual profit and loss statement |
Operating revenue |
|
|
Operating costs |
|
|
Gross profit from operations |
|
|
Operating expenses |
|
|
Net other income (expenses) |
|
|
Net operating income |
|
|
Non-operating income and expenses |
|
|
Profit before tax |
|
|
Tax expense |
|
|
Profit from continuing operations |
|
|
Profit from discontinued operations |
|
|
Profit |
|
|
Other comprehensive income |
|
|
Comprehensive income |
|
|
Basic earnings per share |
|
|
Auditor's report on latest financial statements: auditor's report:
|
Investors may find more detailed information on the company by visiting the Market Observation Post System.。
|
The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.
|